The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma

Ewing sarcomas (ES) are highly malignant, osteolytic bone or soft tissue tumors, which are characterized by EWS–ETS translocations and early metastasis to lung and bone. In this study, we investigated the role of the BRICHOS chaperone domain‐containing endochondral bone protein chondromodulin I (CHM1) in ES pathogenesis. CHM1 is significantly overexpressed in ES, and chromosome immunoprecipitation (ChIP) data demonstrate CHM1 to be directly bound by an EWS–ETS translocation, EWS‐FLI1. Using RNA interference, we observed that CHM1 promoted chondrogenic differentiation capacity of ES cells but decreased the expression of osteolytic genes such as HIF1A, IL6, JAG1, and VEGF. This was in line with the induction of the number of tartrate‐resistant acid phosphatase (TRAP+)‐stained osteoclasts in an orthotopic model of local tumor growth after CHM1 knockdown, indicating that CHM1‐mediated inhibition of osteomimicry might play a role in homing, colonization, and invasion into bone tissues. We further demonstrate that CHM1 enhanced the invasive potential of ES cells in vitro. This invasiveness was in part mediated via CHM1‐regulated matrix metallopeptidase 9 expression and correlated with the observation that, in an xenograft mouse model, CHM1 was essential for the establishment of lung metastases. This finding is in line with the observed increase in CHM1 expression in patient specimens with ES lung metastases. Our results suggest that CHM1 seems to have pleiotropic functions in ES, which need to be further investigated, but appears to be essential for the invasive and metastatic capacities of ES.

[1]  A. Sickmann,et al.  STEAP1 Is Associated with the Invasive and Oxidative Stress Phenotype of Ewing Tumors , 2011, Molecular Cancer Research.

[2]  F. Reinholt,et al.  Osteopontin--a possible anchor of osteoclasts to bone. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[4]  T. Yoneda,et al.  Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. , 2007, Cancer research.

[5]  U. Dirksen,et al.  Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma , 2015, Clinical Cancer Research.

[6]  H. Kovar,et al.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.

[7]  Alison M. Urvalek,et al.  KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9 , 2010, Oncogene.

[8]  B. Swoboda,et al.  Chondromodulin 1 stabilizes the chondrocyte phenotype and inhibits endochondral ossification of porcine cartilage repair tissue. , 2011, Arthritis and rheumatism.

[9]  J. Kondo,et al.  The N-Terminal Cleavage of Chondromodulin-I in Growth-Plate Cartilage at the Hypertrophic and Calcified Zones during Bone Development , 2014, PloS one.

[10]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[11]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[12]  S. Burdach,et al.  DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. , 2013, Cancer research.

[13]  S. Burdach,et al.  Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Kleinerman,et al.  VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL. , 2009, Oncology research.

[15]  M. Murakami,et al.  The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells , 2003, Cell.

[16]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[17]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[18]  E. van Marck,et al.  Isolation of Markers for Chondro-osteogenic Differentiation Using cDNA Library Subtraction , 1996, The Journal of Biological Chemistry.

[19]  M. Ladanyi,et al.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. , 2012, Annual review of pathology.

[20]  Yibin Kang,et al.  Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. , 2011, Cancer cell.

[21]  P. Kasten,et al.  Culture media for the differentiation of mesenchymal stromal cells. , 2011, Acta biomaterialia.

[22]  A. Borkhardt,et al.  Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2 , 2009, Cell cycle.

[23]  M. Katoh,et al.  Comparative genomics on PROM1 gene encoding stem cell marker CD133. , 2007, International journal of molecular medicine.

[24]  U. Dirksen,et al.  Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases , 2010, Bone Marrow Transplantation.

[25]  B. Persson,et al.  BRICHOS - a superfamily of multidomain proteins with diverse functions , 2009, BMC Research Notes.

[26]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[27]  S. Fulda,et al.  G‐Protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP1 , 2013, The Journal of pathology.

[28]  J. Dunst,et al.  Prognostic Impact of Tumor Perfusion in MR-Imaging Studies in Ewing Tumors , 2001, Strahlentherapie und Onkologie.

[29]  M. Kauer,et al.  EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. , 2008, Cancer research.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  J. Chirgwin,et al.  Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment , 2009, PloS one.

[32]  Caiying Guo,et al.  Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation , 2005, Nature Genetics.

[33]  S. Burdach,et al.  High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). , 2002, Critical reviews in oncology/hematology.

[34]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[35]  D. Herrero-Martín,et al.  The molecular pathogenesis of Ewing sarcoma , 2010, Cancer biology & therapy.

[36]  R. Coleman.  Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.

[37]  U. Dirksen,et al.  No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  K. Igarashi,et al.  Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. , 2014, The Journal of clinical investigation.

[39]  Jianning Tao,et al.  One NOTCH Further: Jagged 1 in Bone Metastasis. , 2011, Cancer cell.

[40]  S. Groshen,et al.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. , 2009, Cancer research.

[41]  U. Dirksen,et al.  Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow , 2016, Oncotarget.

[42]  A. Ogose,et al.  Chondromodulin-1 directly suppresses growth of human cancer cells , 2009, BMC Cancer.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  S. Burchill,et al.  Ewing’s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities , 2003, Journal of clinical pathology.

[45]  S. Burdach,et al.  The posterior HOXD locus: Its contribution to phenotype and malignancy of Ewing sarcoma , 2016, Oncotarget.

[46]  A. Chambers,et al.  Role of the metastasis-promoting protein osteopontin in the tumour microenvironment , 2010, Journal of cellular and molecular medicine.

[47]  A. Llombart‐Bosch,et al.  Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma , 2011, The Journal of pathology.

[48]  V. Adhami,et al.  Targeted Knockdown of Notch1 Inhibits Invasion of Human Prostate Cancer Cells Concomitant with Inhibition of Matrix Metalloproteinase-9 and Urokinase Plasminogen Activator , 2009, Clinical Cancer Research.

[49]  Y. Hiraki,et al.  Role of cartilage-derived anti-angiogenic factor, chondromodulin-I, during endochondral bone formation. , 2001, Osteoarthritis and cartilage.

[50]  Shinsuke Yuasa,et al.  Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis , 2006, Nature Medicine.

[51]  Takashi Nakamura,et al.  Methylation in the Core-promoter Region of the Chondromodulin-I Gene Determines the Cell-specific Expression by Regulating the Binding of Transcriptional Activator Sp3* , 2004, Journal of Biological Chemistry.

[52]  Y. Hiraki,et al.  Chondromodulin-I as a novel cartilage-specific growth-modulating factor , 2000, Pediatric Nephrology.

[53]  S. Burdach,et al.  Malignant peripheral neuroectodermal tumours of childhood and adolescence , 2004, Virchows Archiv A.

[54]  H. Inoue,et al.  Identification of Chondromodulin I as a Novel Endothelial Cell Growth Inhibitor , 1997, The Journal of Biological Chemistry.

[55]  G. Várady,et al.  ABCG2 is a selectable marker for enhanced multilineage differentiation potential in periodontal ligament stem cells. , 2015, Stem cells and development.

[56]  A. Valencia,et al.  BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. , 2002, Trends in biochemical sciences.